Asambly Chemicals Co. Ltd.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
News
Home ProductsRanolazine Drug

CAS 5294 61 1 Ranolazine Drug Intermediate Purity 99.0% MIN Powder

I'm Online Chat Now

CAS 5294 61 1 Ranolazine Drug Intermediate Purity 99.0% MIN Powder

China CAS 5294 61 1 Ranolazine Drug Intermediate Purity 99.0% MIN Powder supplier

Large Image :  CAS 5294 61 1 Ranolazine Drug Intermediate Purity 99.0% MIN Powder

Product Details:

Place of Origin: China
Certification: Meet with cGMP requirement

Payment & Shipping Terms:

Minimum Order Quantity: 500Grams
Packaging Details: Drum
Contact Now
Detailed Product Description
Usage: Ranolazine Hydrochloride Intermediate CAS: 5294-64-1
GMP: Yes
High Light:

95635 55 5

,

5294 61 1

 

 

CAS : 5294-61-1 Ranolazine Drug Intermediate Purity 99.0% MIN

 

Chemcial Name : 1- [ ( 2 , 6 - Dimethylanilino ) carbonyl - methyl ) - piperazine  

 

CAS No. 5294-61-1

 

Synonym : N - ( 2 , 6 - Diphenylmethyl ) - 1 - piperazine acetylamine 

 

Molecular Formula : C14H21N3O

 

Molecular Weight : 247.34

 

Specification:

 

Appearance: Off white to white powder or crystalline powder

Loss on drying: Not more than 1.0%

Related substances: Not more than 1.0%

Purity: 99.0% Min

 

Usuage: Ranolazine Intermediate

 

Description:

 

Ranolazine is the active pharmaceutical ingredient (API) of branded drug Ranexa. It was first approved in 2006 by FDA and is now marketed by Gilead Sciences Inc. Ranolazine is used as an antianginal medication. It should be used together with amlodipine, beta-blockers or nitrates. It does not depend upon reductions in heart rate or blood pressure and is the first new anti-anginal in over 20 years.

 

Syntex Inc. originally began the ranolazine development in 1985 and completed 61 studies till1994. Afterwards, Phase II studies were done but it was found that the formulation did not result in adequate plasma concentrations of drug. Then the sustained-release ( SR ) formulation was created.

 

In 1996, CV Therapeutics got the North American and European rights to ranolazine from Syntex accquired by Roche in 1994 and then in 2006, accquired the remaining worldwide rights to ranolazine. In 2008 Menarini accquired exclusively rights for ranolazine in Europe and some other countries from CV and then Gilead accuired CV in 2009. Gilead expanded the partnership with Menarini to include additional countries in 2013.

 

N-(2,6-Dimethylphenyl)-1-piperazine acetamide CAS No. 5294-61-1 is one of its intermediates. The synonyms are N - ( 2 , 6 - Dimethylmethyl ) - 1 - piperazine acetylamine ,  1 - ( N - (2 ,6 - Dimethylphenyl ) carbamoylmethyl ) piperazine and so on. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

 

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.

Contact Details
Asambly Chemicals Co. Ltd.

Contact Person: MAO Xiaolong

Send your inquiry directly to us (0 / 3000)